The findings suggest that many signs and symptoms may improve with time.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
A third COVID-19 vaccine dose increased vaccine effectiveness (VE) against hospitalization from 82% to 97% among adults with healthy immune systems and from 69% to 88% among those with impaired immunity, according to a study today in Morbidity and Mortality Weekly Report (MMWR).
Both studies show promise for boosters against Omicron, with one focusing on dose interval.
Also, the ECDC says the BA.2 subvariant is now dominant in Denmark and is rising elsewhere.
US hospital data show 150,000 COVID-19 patients being treated, down from a record 160,000.
Among 457 adult participants in an ongoing phase 1/2 clinical trial who completed primary COVID-19 vaccination with the Moderna, Johnson & Johnson (J&J), or Pfizer/BioNTech vaccines, a booster dose with either the same (homologous) or a different brand (heterologous) induced an immune response and was safe.
Overall, patients had only modest benefit, but some subgroups fared better.
The US has donated more to COVAX than any other nation, with the latest shipments bound for Pakistan and Bangladesh.
Officials confirmed more than 21 million new global cases last week, the highest weekly total ever.
COVID has compounded how the lack of country-of-origin data can affect drug safety, affordability, availability, and national security.
A large UK study yesterday in PLOS Medicine finds that COVID-19 patients released from the hospital were more than twice as likely as the general population to be rehospitalized or die within the next 10 months. They were also at nearly five times the risk for death from any cause.
